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Summary
The Swiss Cystic Fibrosis Infant Lung Development
(SCILD) cohort is a prospective birth cohort study investi-
gating the initiating events of cystic fibrosis lung disease
during infancy, and their influence on the trajectory of dis-
ease progression throughout early childhood. Infants with
cystic fibrosis are recruited throughout Switzerland after
diagnosis by new-born screening. It is the first European
population-based prospective cohort study of infants with
cystic fibrosis taking advantage of a nationwide new-born
screening programme. The study was established in 2011
and recruitment is ongoing.
The cohort study is currently divided into three study phas-
es (phase 1: diagnosis to age 1 year; phase 2: age 1 to 3
years; and phase 3: age 3 to 6 years). Study participants
have weekly telephone interviews, weekly anterior nasal
swab collection and two study visits in the first year of life.
They also complete follow-up study visits at 3 and 6 years
of age. Data for this study are derived from questionnaires,
lung function measurements, telephone interviews, nasal
swab material and magnetic resonance imaging.
To date, 70 infants have been recruited into the study and
56 have completed phase 1, including a baseline study
visit at 6 weeks of age, weekly surveillance and a study
visit at one year of age. More than 2500 data points on
respiratory health and almost 2000 nasal samples have
been collected. Phases 2 and 3 will commence in 2018.
The dataset of the SCILD cohort combines lung function
data, the collection of environmental and sociodemo-
graphic factors, documentation of respiratory symptoms,
and microbiological analyses. The design not only allows
tracking of the cystic fibrosis lung disease independent of
clinical status, but also surveillance of early disease prior
to severe clinical symptoms.
This cohort profile provides details on the study design
and summarizes the first published results of the SCILD
cohort.
Key words: Swiss Cystic Fibrosis Infant Lung Develop-
ment Cohort (SCILD), cystic fibrosis, longitudinal birth co-
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Introduction
Cystic fibrosis is the most common lethal inherited disease
affecting Caucasian populations, with a prevalence of ap-
proximately 1:3300 [1]. It is a multisystem disorder that
affects exocrine glands including the lung, liver, pancreas
and intestine [2]. Respiratory morbidity is the leading
cause of death, and despite improved survival rates the cur-
rent median survival age of patients with cystic fibrosis is
approximately 40 years [3].
The establishment of new-born screening for cystic fibro-
sis allows diagnosis before the onset of clinical signs [4,
5]. In Switzerland, new-born screening for cystic fibro-
sis was implemented nationwide in 2011 [6]. As not all
patients with cystic fibrosis display overt symptoms dur-
ing the first years of life, new-born screening allows ear-
ly monitoring and treatment of preclinical disease, and a
better understanding of the early disease pathogenesis. It
is now well recognised that in the first months of life in
individuals with cystic fibrosis, pulmonary inflammation,
infection and abnormal lung function are present prior to
clinically diagnosed respiratory illness [7–13]. Therefore,
understanding the pathophysiology of early cystic fibrosis
lung disease is essential to delay its onset and progression,
implement early therapeutic interventions and further im-
prove outcomes.
The Swiss Cystic Fibrosis Infant Lung Development Co-
hort (SCILD) was established in 2011 after implementa-
tion of the Swiss new-born screening for cystic fibrosis
and aims to examine the initiating events of cystic fibrosis
lung disease during infancy and their influence on the tra-
jectory of disease progression throughout early childhood.
The SCILD cohort was set up in a comparable way to
the Bern Basel Infant Lung Development (BILD) cohort
study [14], a prospective birth cohort study of unselected
healthy infants, which was established in 1999. The BILD
and SCILD cohort studies both aim to investigate the phys-
iological properties of the respiratory system, and the en-
vironmental and genetic risk factors that influence lung
development in individuals from infancy throughout child-
hood. The SCILD cohort surveillance protocol has been
only slightly modified from the BILD cohort, and healthy
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infants from the BILD cohort serve as controls for longitu-
dinal measurements performed throughout the study. The
following paragraphs provide details on the study design
and data collection, which have not been published pre-
viously, and give a short summary of current publications
from the SCILD cohort. The reader will thus gain a com-
prehensive and detailed overview of the study.
Overview on the study design
Study design
Infants have been recruited since 2011 following diagnosis
with cystic fibrosis by new-born screening in the cystic fi-
brosis centres of Aarau, Basel, Bellinzona, Bern, Geneva,
Lausanne, Lucerne, St Gallen and Zurich, therefore cover-
ing all of Switzerland. After diagnosis and recruitment at
the treating centre, infant lung function testing is proposed
to all parents of newly diagnosed infants with cystic fibro-
sis (Task Force for cystic fibrosis new-born screening on
behalf of the Swiss Working Group for Cystic Fibrosis).
The University Children’s Hospital Bern is the only centre
in Switzerland currently performing infant lung function
measurements in infants with cystic fibrosis. Study enrol-
ment occurs on the day of lung function testing at the age
of around 10 weeks, irrespective of prior clinical symp-
toms. The study is performed in Bern and was approved by
the Ethics Committee Bern, Switzerland. Written informed
consent is obtained from the parents. Exclusion criteria in-
clude the need for respiratory support for more than 3 days
after birth, severe comorbidities or known diseases other
than cystic fibrosis, maternal drug abuse, other known se-
vere maternal diseases and severe problems of communi-
cation.
The study design of the SCILD cohort is divided into three
phases as shown in figure 1. Details on data assessment at
each study time point are displayed in table 1.
Phase 1
The first study phase begins with recruitment after infants
have been diagnosed with cystic fibrosis following new-
born screening and continues throughout the first year of
life. Informed written consent is collected at the baseline
study visit when the infants are around 10 weeks of age.
Throughout phase 1, a study nurse contacts parents weekly
by telephone. Phase 1 concludes following the first follow-
up visit, which is scheduled for when the child reaches 1
year of age.
Phase 2
The second study phase starts after the first follow-up visit
at age one and continues until the second follow up visit at
the age of 3 to 4 years for all infants born after 2014. Res-
piratory and environmental history during phase 2 will be
assessed retrospectively at the second follow up visit.
Phase 3
The third study phase starts after the second follow up at
age 3 to 4 years and continues until the third follow up visit
at the age of 6 years. Respiratory and environmental his-
tory during Phase 3 will be assessed retrospectively at the
third follow-up visit.
Data sources and variables
Data acquisition is based on the study design of the BILD
cohort [14]. Data are derived from the following sources:
(1) questionnaires, (2) lung function measurements, (3)
telephone interviews, (4) nasal swab samples, 5) respirato-
Figure 1: Design of the SCILD cohort study – flow chart of data collection.NBS = new-born screening; FeNO = exhaled nitric oxide; MBW =
multiple breath washout, SBW = single breath washout; MRI = magnet resonance imaging
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ry rate measurements, (6) skin prick tests, and (7) function-
al and morphological magnetic resonance imaging (MRI)
Table 1: Details of data collection from the different sources in the SCILD study.
Sources Details of data collection
1. Standardised questionnaires [14–17]
Questionnaire 1 • Pets and exact type of pet at home, during/after pregnancy
• Type of heating, type of stove, chimney, open fire-place
• Sleeping environment child (mattress, encasement, sheepskin rug use)
• Damage due to damp at home, assessment of exposure to mould
• Maternal active or passive smoking, ETS smoke exposure, number of cigarettes, smoking cessation and first year of life
• Maternal intake of coffee/tee, caffeine containing soft drinks, vitamin supplement intake, fruit intake
• Maternal treatment with antibiotics, steroid treatment during pregnancy
• Respiratory infections, gastrointestinal infections, urinary tract infections, other infections during pregnancy
• Paternal active smoking, number of cigarettes, smoking cessation during pregnancy and first year of life
Questionnaires 2–5 • Infections, colds (especially upper and lower respiratory tract, ear, nose, throat), number and duration
• Exacerbations of disease (number, severity)*
• Number, reason and course of hospitalisations†
• Medication, especially antibiotics since last study visit, alternative medications and remedies used
• Quality of life [17]: limits in physical activity/ ability to participate in social activities / mental health (depression, listlessness)
• Atopic disease: atopic rhinitis or conjunctivitis, asthma (severity), atopic dermatitis
• Behavioural problems, enuresis (primary, secondary, diurnal, nocturnal)
• Level and impairment of indoor and outdoor activity, type of activity
• Pets and exact type of pet at home
• Farming exposure, animal type
• Traffic exposure at home (trucks)
• Type of heating, type of stove, chimney, open fire-place
• Living condition (type of dwelling, rural/urban, number of rooms, number of people in household)
• Diet (fruit, vegetables, sweets, chocolate, fast food, snacks, unpasteurized milk)
• Maternal and paternal active or passive smoking, ETS exposure, number of cigarettes, smoking cessation until first major follow-
up at age 3 and 6 years
2. Lung function measurements
Infant lung function 1. Tidal breathing measurements [18, 19]:
• Ultrasonic flowmeter (Spiroson®, EcoMedics AG, Duernten, Switzerland) with infant face mask
• Main outcome parameters: tidal volume, minute ventilation, respiratory rate
2. Measurement of FENO [20]:
• Rapid-response chemoluminescence analyser (CLD 88, EcoMedics AG, Duernten, Switzerland), with a range of 0–100 ppb, in-
fant face mask
• Breath-by-breath measurement
• Main outcome parameter: mean FENO
3. Multiple breath washouts (SF6) [21]:
• Ultrasonic flowmeter (see above), infant face mask
• Main outcome parameters: lung volume (FRC) and ventilation inhomogeneity (LCI)
Preschool lung function 1. Tidal breathing measurements:
• Quiet tidal breathing
• Ultrasonic flowmeter with mouth-piece, filter and nasal clamp
• Main outcome parameters: minute ventilation (tidal volume multiplied by respiratory rate) and expiratory flow
2. Measurement of FENO [20]:
• Rapid-response chemoluminescence analyser (CLD 88, EcoMedics AG, Duernten, Switzerland), with a range of 0–100 ppb
• Breath-by-breath measurement and single-breath manoeuvre, with mouth-piece, no nasal clamp
• Main outcome parameter: mean FENO
3. Multiple breath washouts (N2):
• Ultrasonic flowmeter (see above), mouthpiece, filter, nasal clamp
• Main outcome parameters: lung volume (FRC) and ventilation inhomogeneity (LCI)
4. Single breath washouts (helium, SF6)
• Ultrasonic flowmeter (see above), mouthpiece, filter, nasal clamp
• Main outcome parameters: Sacin, Scond
5. Spirometry (body plethysmography):
• MasterScreen Body, Jaeger, Germany, mouthpiece, filter, nasal clamp
• Main outcome parameters: lung volume (FRC, intrathoracic gas volume), forced expiratory flows and volumes
3. Telephone interviews • Respiratory symptoms (including cough and wheeze during day and night, difficulty breathing, reduced activity)
• Standardised score to group symptoms into four levels according to severity and with high sensitivity for lower respiratory tract in-
fections
• Main outcome parameter: weeks with severe respiratory symptoms (defined as total number of weeks with day/night score of ≥3
• Any changes in environment such as moving, pets, smoking habits, childcare, breastfeeding, nutrition
• Medication, e.g., exact time point, kind and duration of antibiotics
3. Nasal swabs • Microbiota analysis: microbiota assessment with PCR amplification of the 16S ribosomal RNA (rRNA) gene and 454 amplicon se-
quencing as described previously [22, 23]
• Virological analysis: real-time (7 duplex) PCR will be used to used detect respiratory viruses as previously described [24]
4. Respiratory rate measurements • Assessed over 60 seconds by hand on infant’s chest in quiet sleep state
• Assessed over 60 seconds by a study nurse in awake children at study visit 3 and 4
6. Skin prick test • Dog dander, cat dander, Dermatophagoides pteronyssinus, mixed tree pollens, mixed grass pollens, Alternaria tenuis, positive
control (histamine), negative control (NaCl) (Allergomed, Switzerland)
7. Magnetic resonance imaging • Starting in 2018
• Matrix pencil decomposition, a new functional MRI method
• Morphological MRI
• Main outcome: ventilation and perfusion indices
ETS = environmental tobacco smoke; FENO = exhaled nitric oxide; FRC = functional residual capacity; LCI = lung clearance index, MRI = magnetic resonance imaging; PCR =
polymerase chain-reaction * Pulmonary exacerbation is defined as any increase in respiratory symptoms from baseline that require a doctoral visit and additional treatment and/
or decline in lung function measurement. † Specific reasons for hospitalisations are documented including respiratory, gastrointestinal problems or any other.
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(planned for 2018). Details on the specific time points for
assessments are displayed in figure 1. Further details of da-
ta collection are displayed in table 1.
Data collection
1. Standardised questionnaires
Questionnaire one is administered at the baseline study
visit [15, 16]. It is a validated questionnaire that has
been used previously in the BILD cohort and other
birth cohort studies [15, 16]. Information about health
conditions, sociodemographic and environmental ex-
posures are assessed, including pre-, peri-, and postna-
tal risk factors and family history. Questionnaires two
to five will be used during phases 2 (at second follow
up visit) and 3 (at the third follow up visit) [14]. Parent
and child versions of the validated cystic fibrosis ques-
tionnaire (CFQ-R) [17, 25] are used to assess disease-
specific health-related quality of life in patients with
cystic fibrosis. In addition, we collect data from two
previously validated questionnaires used in the BILD
study to assess overall respiratory health [14]. Details
on the assessed data are provided in table 1.
2. Lung function measurements
Infant lung function measurements are performed at
the age of 4 to 12 weeks (baseline study visit) during
quiet natural sleep in the supine position, and at the
age of 1 year (first follow up visit) under sedation with
chloral hydrate (75–100 mg/kg bodyweight, applied
rectally) according to current guidelines for infant lung
function testing [26–28]. Preschool lung function mea-
surement is performed in awake children at the second
(age 3 to 4 years) and third (age 6 years) follow-up
visit. Preschool lung function measurements are per-
formed in a seated, upright position during regular
breathing according to current guidelines [29, 30]. De-
tails on the lung function tests and their outcome para-
meters are provided in table 1.
3. Weekly telephone interviews
Throughout the first year of life study nurses conduct a
standardized weekly telephone interview to track res-
piratory health. A standardised score (equivalent to
the BILD cohort) with high sensitivity to detect lower
respiratory tract infections will be calculated [31]. In
addition, the questionnaire documents changes in so-
ciodemographic and environmental exposures, med-
ical history and antibiotic use (table 1).
4. Nasal swab material
An anterior nasal swab (FLOQSwabs™, in UTM-
RT™, Copan, Italy) is collected weekly during phase
1 by parents, who are instructed by study nurses about
correct and standardised swab sampling. In addition,
monthly nasal swabs at home and quarterly oropha-
ryngeal swabs at clinic visits will be collected during
phase 2 (throughout the year the child is 3 years of
age) and phase 3 (throughout the year the child is
6 years of age). Immediately after collection, nasal
swabs are sent to our study centre and frozen at −80°C
until further processing. Microbiological detection and
quantification of viruses and bacteria are performed
in specialised laboratories specified in table 1. These
analyses are for research purposes only and have no in-
fluence on the clinical treatment of the participants.
5. Respiratory rate
During the first year of the infant’s life, parents mea-
sure the respiratory rate every week. At the baseline
study visit, parents are instructed by study nurses how
to correctly measure respiratory rate in the home set-
ting. The respiratory rate is measured for 60 seconds in
quiet sleep (non-rapid eye movement), excluding peri-
ods of active sleep state, by the parents placing their
hand on the child’s chest. At the second and third fol-
low-up visit respiratory rate is measured by a study
nurse in awake children.
6. Skin prick test
A maternal skin prick test is performed at baseline
study visit and a child skin prick test at the third fol-
low-up visit at 6 years of age. Details on tested aller-
gens are provided in table 1.
7. Functional and morphological chest MRI (planned for
2018)
We plan to establish chest MRI in the SCILD cohort
at the follow-up visits at the age of three to four and
six years, beginning in 2018. To overcome the need
for contrast agents, a new functional MRI technique,
termed matrix pencil decomposition, a derivative of
the Fourier decomposition method, was developed for
evaluation of regional ventilation and perfusion im-
pairment of the lung [32–36]. This novel MRI tech-
nique provides visual and numerical information on
functional deficits in perfusion and ventilation of the
lung, without the need for intravenous contrast, in-
haled tracers or breath-holding manoeuvres [37].
Functional MRI has the potential to detect ventilation
and perfusion impairment, which may be the earliest
and reversible manifestations of cystic fibrosis lung
disease [37]. Morphological assessment will be based
on a protocol previously described by Eichinger et al.
for MRI in cystic fibrosis [38]. MRI has not been per-
formed in the BILD cohort yet, but is also planned for
the future.
We attempt to access data from each source in every par-
ticipant; however, it is not mandatory to participate in all
aspects of data collection, such as weekly nasal swab sam-
pling and/or respiratory rate measurements, and infant lung
function tests are also optional. The latter did not yet apply
to any potential participants. In addition, they do not have
to attend every study phase.
Study participants
At end of 2017, 70 infants with cystic fibrosis had been re-
cruited in the SCILD study. Of these, 56 (80%) have com-
pleted the first year of study, and 14 (20%) have not yet
reached one year of age and are still completing the first
study phase.
Details on demographic data can be found in table 2. To
date there have been no infants lost to follow up in phase
1 of the study and all infants completed the first year of
the study. The second and third follow-up visits will begin
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in 2018. Recruitment is ongoing, with approximately 9 to
13 newly diagnosed infants recruited per year (incidence of
cystic fibrosis diagnosed by new-born screening approxi-
mately 25/year [1]); for details see table 3.
Summary of published studies from the
SCILD cohort
Publications to date have focused primarily on longitudinal
microbial and viral analyses of the nasal swab material and
infant lung function measurements over the first year of
life [24, 39, 40, 41]. All studies have included healthy in-
fants from the BILD cohort as control group.
Composition of the nasal microbiota in infants with
cystic fibrosis
The microbiota is known to play an important role in hu-
man health, with important influences on early adaptive
immunity and innate resistance to infection [42, 43]. Re-
cent studies suggest that diversity of the microbiota is low-
er in children with cystic fibrosis than in healthy chil-
dren, and diversity decreases following the onset of chron-
ic Pseudomonas infection [44–46]. However, little is
known about the entire composition of the upper respi-
ratory tract microbiota in infants with cystic fibrosis. We
analysed the nasal microbiota longitudinally in 30 infants
with cystic fibrosis (461 samples) compared with 47
healthy controls (872 samples). We identified composi-
tional differences in the microbiota of infants with cystic
fibrosis compared with healthy controls [39]. Furthermore,
a disordered microbiota was found following antibiotic ad-
ministration. Our data indicate that the microbiota is al-
tered in infants with cystic fibrosis and that early antibi-
otic therapy influences the microbiota. These findings can
be used to inform future studies on the effect of antibiotic
treatment on the microbiota in infants with cystic fibrosis,
and might be of importance in prevention of early disease
progression [39].
Role of viral colonisation in early cystic fibrosis lung
disease
Acute viral respiratory tract infections in children and
adults with cystic fibrosis play a significant role in mor-
bidity and mortality [47]. However, data about viral detec-
tion during infancy remains scarce [48]. We assessed 12
different respiratory viruses in 31 infants with cystic fibro-
sis (665 samples) and 32 healthy infants (712 samples) in a
prospective longitudinal study during the first year of life.
By weekly monitoring of respiratory symptoms, we could
distinguish between asymptomatic and symptomatic viral
detection. In our study, viral detection was not more fre-
quent in cystic fibrosis infants than in healthy controls, and
infants with cystic fibrosis were less symptomatic when a
virus was present. We can only speculate about underly-
ing reasons, but local epithelial properties, immunological
mechanisms and even early treatment could play a role in
viral detection and symptoms at the time of detection in
early cystic fibrosis lung disease [24].
Lung function measurements in cystic fibrosis infants
It is unknown at what age lung function impairment may
arise in children with cystic fibrosis. We assessed lung
function (multiple breath washout and tidal breathing para-
meters) shortly after birth in 53 infants with cystic fibrosis
diagnosed by new-born screening and 57 healthy controls.
We reported that more than 40% of eight-week-old infants
with cystic fibrosis showed abnormal lung function inde-
Table 2: Demographic details of the study population.
Mean Standard deviation Total number of measurements
Gestational age (weeks) 39.2 1.5 70
Birth height (cm) 49 1.8 70
Birth weight (kg) 3.2 0.4 70










Results are displayed as total numbers if not stated otherwise. To date, 70 infants with cystic fibrosis have been included in the study, of whom 56 have completed study phase 1.
* In two infants lung function measurements were not successful, because no quiet, regular sleep episode could be obtained. † All infants are included, standard deviations are
large, as some infants just started the study period and data collection is still ongoing




(2011–2016) 2012 2013 2014 2015 2016 2017
Infants with CF detected by
NBS*
56 19 35 20 23 n.a.‡ 153
Recruited after positive NBS† 9 12 8 9 8 10 14 70
Completed
study phase 1
9 12 8 9 8 10 – 56
Drop-outs during study phase 1 – – – – – – – –
Phase 2
(starts in 2018)
– – – – 2018/19 2019/20 2020/21
Phase 3
(starts in 2018)
2018 2018 2019 2020 2021 2022 2023
CF = cystic fibrosis; NBS = new-born screening * Infants that were diagnosed with CF throughout Switzerland † Infants that were recruited in the SCILD study ‡ Numbers for
2017 are not yet available
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pendent of clinical symptoms and previous therapeutic ap-
proaches. Ventilation inhomogeneity or hyperinflation may
serve as noninvasive markers for monitoring cystic fibro-
sis lung disease and specific treatment effects, and could
thus be used as outcome parameters for future intervention
studies in this age group [40].
Lower exhaled nitric oxide in infants with cystic fibro-
sis
The fractional concentration of exhaled nitric oxide (FENO)
is a well-known biomarker for airway inflammation and is
elevated in a number of inflammatory lung diseases [49].
However, despite chronic severe airway inflammation in
patients with cystic fibrosis, FENO levels are decreased
[50]. In order to understand whether reduced FENO in cys-
tic fibrosis airways is primarily related to the loss of func-
tion of the cystic fibrosis transmembrane regulator (CFTR)
or an epiphenomenon of chronic inflammation, we mea-
sured FENO in infants with cystic fibrosis and healthy con-
trols at the age of 5 to 12 weeks prior to first respiratory
infection. Airway FENO was reduced in young infants with
cystic fibrosis, and the effect was more pronounced in in-
fants with two copies of class I and/or II mutations and
thus without CFTR function [41]. Hence, low FENO levels
in cystic fibrosis airways shortly after birth are likely to be
associated with underlying CFTR dysfunction. As reduced
levels of FENO have been linked to a number of adverse ef-
fects, including effects on the defence mechanisms of the
respiratory tract, this finding might open up a new chapter
of research in the field of early FENO measurements in pa-
tients with cystic fibrosis.
Conclusion
Summary
The SCILD cohort includes infants with cystic fibrosis
from early infancy until childhood recruited throughout
Switzerland. Therefore, the course of the disease can be
prospectively followed throughout early childhood. The
dataset of the SCILD cohort combines lung function data,
collection of environmental and sociodemographic factors,
documentation of respiratory symptoms, and microbiolog-
ical analyses. Lung function surveillance at several time
points (after birth, at 1, 3 to 4, and 6 years of age) allows
data collection during important phases of lung develop-
ment. Weekly questionnaires and surveillance during the
first year of life allow close monitoring during both asymp-
tomatic and symptomatic episodes of the disease. This
study design has resulted in over 2500 data points about
respiratory health being collected to date and almost 2000
nasal samples being collected. This design not only allows
tracking of the cystic fibrosis lung disease independent of
clinical status, but also surveillance of early disease prior
to severe clinical symptoms.
Strengths and limitations
The SCILD cohort is the only prospective birth cohort in-
vestigating cystic fibrosis disease in Switzerland and the
third ever established in the world, in addition to the Aus-
tralian Respiratory Early Surveillance Team for Cystic Fi-
brosis (AREST CF) and the London Cystic Fibrosis Col-
laboration (LCFC) [51]. The latter cohort, however, re-
cruits from centres in London only. Whereas all three co-
horts focus on lung function measurements and aim to find
diagnostic tools to monitor early lung impairment [52–54],
novel aspects of the SCILD study are the close moni-
toring by weekly nasal sampling and phone calls. With
the newly developed MRI imaging technique, there is no
need for radiation or sedation [37, 55]. Furthermore, re-
sults are always compared with a contemporary healthy
control group, the BILD cohort, for whom data are collect-
ed at the same study centre with a similar study design and
setting. This comparability throughout the study period is
an important feature of our study population.
The incidence of cystic fibrosis in Switzerland is approx-
imately 1:3300 live births [1], thus the number of infants
diagnosed with cystic fibrosis per year is relatively low
in Switzerland (incidence approximately 25/year [1]). In
previous years, logistical and disease-specific factors (e.g.,
prolonged hospital stay of infants due to meconium ileus,
parents who are not able to travel to Bern for the measure-
ments because of long travel distances, delayed diagnosis
of cystic fibrosis after the age of 15 weeks) have led to a
lower than expected number of recruited patients, which is
a weakness of the study. Specific questions (e.g., stratify-
ing by the different causative mutations) might not be pos-
sible until additional subjects are recruited, as numbers are
too low for certain subgroup analyses. However, continued
recruitment of newly diagnosed infants with cystic fibro-
sis and healthy controls throughout the planned follow-up
period will ensure numbers sufficient to address the aim to
investigate the physiological properties of the respiratory
system and detect risk factors that influence lung develop-
ment.
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